TG Therapeutics, Inc.
TGTX
$34.35
-$3.00-8.03%
| Weiss Ratings | TGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | B | |||
| Rating Factors | TGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Good | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.80 | |||
| Price History | TGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -14.55% | |||
| 30-Day Total Return | 18.37% | |||
| 60-Day Total Return | 19.40% | |||
| 90-Day Total Return | -2.05% | |||
| Year to Date Total Return | 10.59% | |||
| 1-Year Total Return | 136.57% | |||
| 2-Year Total Return | 118.65% | |||
| 3-Year Total Return | 228.08% | |||
| 5-Year Total Return | 259.31% | |||
| 52-Week High % Change | -13.78% | |||
| 52-Week Low % Change | 188.86% | |||
| Price | TGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $43.32 | |||
| 52-Week Low Price | $12.93 | |||
| 52-Week Low Price (Date) | Apr 30, 2024 | |||
| 52-Week High Price (Date) | Mar 24, 2025 | |||
| Valuation | TGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 5.42B | |||
| Enterprise Value | 5.37B | |||
| Price/Earnings (TTM) | 273.43 | |||
| Earnings Per Share (TTM) | 0.14 | |||
| Earnings Per Share Growth | 1,308.25% | |||
| Price/Earnings To Growth | 0.21 | |||
| Price/Sales (TTM) | 18.19 | |||
| Price/Book (Q) | 24.19 | |||
| Enterprise Value/Revenue (TTM) | 16.31 | |||
| Price | $34.35 | |||
| Enterprise Value/EBITDA (TTM) | 127.81 | |||
| Enterprise Value/EBIT | 128.02 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | TGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 160.24M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 212 554 4484 | |||
| Address | 3020 Carrington Mill Blvd. Morrisville, NC 27560 | |||
| Website | www.tgtherapeutics.com | |||
| Country | United States | |||
| Year Founded | 1993 | |||
| Profitability | TGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 12.74% | |||
| Profit Margin | 7.10% | |||
| Management Effectiveness | TGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 5.78% | |||
| Return on Equity | 12.21% | |||
| Income Statement | TGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 329.00M | |||
| Total Revenue (TTM) | 329.00M | |||
| Revenue Per Share | $2.05 | |||
| Gross Profit (TTM) | 290.52M | |||
| EBITDA (TTM) | 42.00M | |||
| EBIT (TTM) | 41.93M | |||
| Net Income (TTM) | 23.38M | |||
| Net Income Avl. to Common (TTM) | 23.38M | |||
| Total Revenue Growth (Q YOY) | 146.04% | |||
| Earnings Growth (Q YOY) | 261.84% | |||
| EPS Diluted (TTM) | 0.14 | |||
| EPS Diluted Growth (Q YOY) | 248.76% | |||
| Balance Sheet | TGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 311.00M | |||
| Cash Per Share (Q) | $1.94 | |||
| Total Current Assets (Q) | 566.36M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 222.36M | |||
| Current Ratio (Q) | 6.246 | |||
| Book Value Per Share (Q) | $1.54 | |||
| Total Assets (Q) | 577.69M | |||
| Total Current Liabilities (Q) | 90.68M | |||
| Total Debt (Q) | 254.38M | |||
| Total Liabilities (Q) | 355.33M | |||
| Total Common Equity (Q) | 222.36M | |||
| Cash Flow | TGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.04M | |||
| Cash from Financing (TTM) | 128.53M | |||
| Net Change in Cash (TTM) | 86.97M | |||
| Levered Free Cash Flow (TTM) | -62.10M | |||
| Cash from Operations (TTM) | -40.52M | |||
